TRAX earnings: next report 2026-08-07, real EPS beat/miss history, P/E -13.58. Updated 2026-07-23.
First Tracks Biotherapeutics (TRAX) Research Hub
First Tracks Biotherapeutics (TRAX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 36.44 USD (-7.91%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -13.58, market cap 1.33B. This hub links to the full technical, earnings and options research available for TRAX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 36.44 USD (-7.91%) |
| 52-week range | 15.71 USD – 49.91 USD |
| Trend regime | Range |
| 14-day RSI | 32.1 (Bearish) |
| Trailing P/E | -13.58 |
| Market cap | 1.33B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-07 |
Available research for TRAX
Covered Call on TRAX: how it works, illustrative setup around the real 36.44 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TRAX: how it works, illustrative setup around the real 36.44 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TRAX: how it works, illustrative setup around the real 36.44 USD price, max profit/loss, breakeven and when to use it. Educational.
TRAX technical analysis: range, last 36.44 USD, RSI 32.1, 52w range 15.71 USD–49.91 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TRAX in?
First Tracks Biotherapeutics (TRAX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TRAX in an uptrend or downtrend?
As of 2026-09-11, TRAX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TRAX's trailing P/E ratio?
TRAX's trailing P/E is -13.58, with a market cap of 1.33B. See the earnings research page for full valuation detail.
When does TRAX next report earnings?
TRAX is next scheduled to report earnings on 2026-08-07, with a consensus EPS estimate of -0.80256 USD.